GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Construction In Progress

ABL Bio (XKRX:298380) Construction In Progress : ₩71,880 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Construction In Progress?

ABL Bio's quarterly construction in progress increased from Sep. 2023 (₩325 Mil) to Dec. 2023 (₩70,491 Mil) and increased from Dec. 2023 (₩70,491 Mil) to Mar. 2024 (₩71,880 Mil).

ABL Bio's annual construction in progress stayed the same from Dec. 2021 (₩0 Mil) to Dec. 2022 (₩0 Mil) but then increased from Dec. 2022 (₩0 Mil) to Dec. 2023 (₩70,491 Mil).


ABL Bio Construction In Progress Historical Data

The historical data trend for ABL Bio's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Construction In Progress Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial - - - - 70,491.09

ABL Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 231.10 325.06 70,491.09 71,880.10

ABL Bio Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


ABL Bio (XKRX:298380) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines